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Summary 
Integrin CR3 (CD11b/CD 18, Mac-l, 0~a[32) mediates the transient adhesion of polymorpho- 
nuclear  leukocytes  (PMN)  to  surfaces  coated  with  fibrinogen,  C3bi,  ICAM-1,  and  other 
ligands.  Recent studies (Cai, T.-Q., and S.D. Wright. 1995.J.  Biol.  Chem.  270:14358) suggest 
that adhesion may be favored by stimulus-dependent changes in the kinetics of ligand binding 
by CR3.  Cell detachment, on the other hand, must occur by a different mechanism because 
binding kinetics  cannot affect cell adhesion  after binding of ligand  has  occurred.  We  have 
sought a mechanism that would reverse binding of ligand to CR3 and report here that lysates 
of PMN contain an endogenous ligand that binds CR3 and competes the binding of C3bi. Pu- 
rification and sequence analysis identified the structurally homologous azurophilic granule pro- 
teins, elastase, protease 3, and azurocidin as candidates. Studies with purified elastase and azuro- 
cidin showed that each bound specifically to purified, immobilized CR3.  Elastase  may play a 
role in modulating integrin-mediated ceil adhesion because it is expressed at the cell surface, 
and the expression level is inversely proportional to cell adhesivity. Furthermore, a monoclonal 
antibody against  elastase prevented detachment of PMN from fibrinogen-coated surfaces  and 
blocked chemotaxis, confirming a role for this protein in regulating integrin-mediated adhe- 
sion. These studies suggest a model for release of integrin-mediated cell adhesion in which en- 
dogenous ligands  such as elastase may release adhesion by "eluting" substrate-bound ligand. A 
role for the proteolytic activity of elastase appears likely but is not demonstrated in this study. 
p MN  respond to  chemoattractants with  a transient in- 
crease in adhesivity (1,  2).  This process results  in firm 
attachment to endothelial cells, and the subsequent decline 
in adhesivity allows migration of PMN out of the vascula- 
ture. Cycles of cell adhesion (at the leading edge) and re- 
lease  (at the uropod) are further thought to underlie loco- 
motion of adherent PMN.  Transient adhesion of PMN is 
mediated by the leukocyte integrin CR3  (CD11b/CD18, 
Mac-l, {~M~2), which exhibits rapid changes in binding to 
immobilized ligands such as ICAM-1, fibrinogen, and com- 
plement protein C3bi in response to chemoattractants (3-5). 
CR3 can be isolated from PMN in two forms, one that 
binds ligand and one that does not (6, 7). Purified, inactive 
CR3  becomes  capable  of binding ligand  upon  treatment 
with  cellular lipids  (7)  or with  the  activating mAb  KIM- 
127 (6, 8). It has thus been assumed that regulated binding 
is a property of the CR3 itself] an increase in the affinity of 
CR3  for ligand could promote adherence, and a decrease 
could promote detachment (9). 
Recent  work  with  purified  CR3,  however,  has  chal- 
lenged  the  view  that  changes  in  the  binding  affinity  of 
CR3 mediate both adhesion and detachment. Transforma- 
tion of purified, inactive CR3 to active CR3 was found to 
be isoenergetic  (6).  Activating stimuli  thus  may promote 
binding  of ligand  by  altering  the  binding  kinetics  rather 
than the affinity. Although altering binding kinetics could 
readily explain enhancement of cell adhesion, it cannot ex- 
plain the thermodynamically unfavorable release of ligand 
required for cell detachment. On a cellular level, these re- 
suits suggest that changes in CR3 could initiate cell adhe- 
sion  but  could  not  drive  detachment  without  additional 
cellular components.  We  have therefore sought  evidence 
for a  species  that  could reverse the  binding  of ligand  to 
CR3.  We discovered an abundant  endogenous ligand for 
CR3 that appears necessary for detachment of PMN from 
fibrinogen-coated surfaces. 
Materials and Methods 
Reagents and Antibodies 
Reagents.  Immunopure  biotin N-hydroxysuccinimido  (NHS) 
was purchased from Pierce Chemical Co.  (Rockford, IL). N-octyl 
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imidyl 3-(2-pyridithio)  propionate  (SPDP),  diisopropyl fluoro- 
phosphate  (DFP),  and  recombinant  human  complement  C5a 
were  from Sigma Chemical Co.  (St.  Louis, MO).  GammaBind 
G-Sepharose  was  from  Pharmacia Biotech  AB  (Uppsala,  Swe- 
den).  Streptavidin-conjugated  horseradish  peroxidase  and  the 
ECL  TM  Western blot detection kit were  from Amersham Corp. 
(Arlington Heights, IL). Dulbecco's PBS was from BioWhittaker 
(Walkersville,  MD).  A  fluorogenic substrate  for  alkaline phos- 
phatase,  Attophos,  was  from  JBL  Scientific,  Inc.  (San  Luis 
Obispo, CA). All protease inhibitors, streptavidin-conjugated al- 
kaline phosphatase,  and human plasma fibrinogen (plasminogen 
free)  were from Calbiochem-Novabiochem Corp. (La Jolla, CA). 
5- (and 6-)  carboxyfluorecein diacetate,  succinimidyl ester  (CFSE) 
was from Molecular Probes,  Inc. (Eugene, OR).  Human serum 
albumin (HSA)  was  from Armour Pharmaceutical Co.  (Kanka- 
kee,  IL).  Human leukocyte elastase  (HLE)  was  purchased  from 
Elastin Products (Owensville, MS). According to the supplier, the 
elastase  was  chromatographically purified from  purulent human 
sputum,  was  >95%  pure,  and was  free  from  cathepsin G,  my- 
eloperoxidase,  and lysozyme. Azurocidin prepared  as previously 
described (10)  was a gift from Dr. J.  Gabay (Cornell University 
Medical College, New York). 
mAbs.  IB4  (anti-CD18) (5),  OKM-1  (anti-CDllb)  (5),  44a 
(anti-CD1 lb) (11),  3C10 (anti-CD14) (12), and 60b (anti-CD14) 
(13)  were  as previously described and are all available from the 
American Type Culture Collection (Rockville, MD).  KIM-127 
(anti-CD18) (14)  was a gift from Dr.  M.K.  Robinson (Celltech 
Ltd., Berkshire, UK). NP57  (anti-HLE) (15) was purchased from 
the Accurate Chemical and Scientific Corp. (Westbury, NY). no. 
204  (anti-HLE)  was  from  BIODESIGN  International (Kenne- 
bunkport, ME). 
Polyclonat Antibodies.  Rabbit anti-HLE was from BIODESIGN 
International. Rabbit anti-CR3 was as previously described (16). 
FITC-conjugated goat  anti-rabbit IgGF(ab')2  was  from  Boeh- 
ringer Mannhein Corp. (Indianapolis, IN). 
Purification  of Active  CR3 
CR3 was purified from PMN using antibody affinity chroma- 
tography  as  described  (6).  Briefly,  pellets  of PMN  prepared  as 
previously described  (6)  were  lysed with buffer containing 100 
mM Tris, pH 8.0, 150 mM NaC1, 2 mM MgC12, 2% OG, 0.02% 
NaN> and protease inhibitors for 1 h at 4~  The lysate was then 
centrifuged at 35,000 g for 30 rain. The supernatant was collected 
and passed  over an IB4 (anti-CD18) immunoaffinity column. Af- 
ter a thorough wash,  CR3 was eluted with buffer containing 50 
mM triethylanfine, pH  11.0,  150 mM NaC1, 2 mM MgC12,  1% 
OG  into  tubes  with  neutralizing buffer  (15%  by  volume  1  M 
Tris-HC1, pH  7.4).  CR3  was  then dialyzed against PBS,  0.02% 
NaN  3. CR3 purified by this method will bind its ligand and is re- 
ferred to as active CR3. 
Biotinylation  of Soluble Proteins from PMN 
Pellets of PMN,  prepared  as previously described  (6)  except 
that all protease  inhibitors were  excluded, were  lysed with  100 
mM sodium borate, pH 8.5,  150 mM NaC1, 2% OG, for 30 min 
I  Abbreviations used in this paper: AP, alkaline phosphatase; CFSE, 5- (and 
6-) carboxyfluorecein diacetate succinimidyl ester; DFP, diisopropyl fluo- 
rophosphate; HLE, hmnan leukocyte elastase; HSA, human serum albu- 
min; NHS, N-hydroxysuccinimido;  OG, N-ocwl /8-D-glucopyranoside; 
SPDP, ,-succinimidyl  3-(2-pyridithio) propionate. 
at 4~  with stirring. The lysate was centrifuged at 35,000 g for 30 
rain. The supernatant was collected and biotinylated by addition 
of 2  mg/ml of immunopure biotin NHS.  After 15 nfin incuba- 
tion on ice, an equal volume of 1 M  NH4C1 was added to stop 
the biotinylation. Excess biotin NHS was removed by gel filtra- 
tion on a NAP-25 column (Pharmacia LKB,  Uppsala,  Sweden) 
equilibrated with PBS and 0.25% OG. 
Purified proteins to be biotinylated were first  dialyzed against 
100 mM sodium borate buffer with 150 mM NaC1, pH 8.5. After 
dialysis, the proteins were biotinylated as described above. 
Binding of Biotinylated Soluble Proteins  to 
Immobilized CR3 
To measure the binding of biotinylated proteins to CR3, 72- 
well Terasaki plates (Robbins Scientific Corp., Mountain View, 
CA) were coated with 10 hal/well (~10 I.zg/ml)  of purified CR3 
diluted in PBS and 0.02% NaN  3 for 2 h at 4~  Wells were aspi- 
rated and then blocked with 10% dry milk dissolved in PBS for 1 h 
at 4~  After four washes with PBS, 10 btl biotinylated PMN ly- 
sate or biotinylated purified proteins diluted in PBS with 0.1% of 
milk were added to each well. Plates were incubated at 37~  for 
1 h. After four washes with PBS, 10 ~l/well ofstreptavidin-con- 
jugated alkaline phosphatase  (1:1,000) were added and incubated 
for 45 min on ice. After four washes with PBS, 5 I.fl/well ofa fluo- 
rogenic substrate for alkaline phosphatase  (AP)  were added.  The 
fluorescence  signal  generated  at  21~  was  detected  over  time 
with  a  fluorescence  plate  reader  (Cytofluor  TM  2300;  Millipore 
Corp, Bedford, MA). The amount ofbiotinylated protein bound 
to CR3-coated plates was expressed as the change in arbitrary flu- 
orescence  units over a  fixed  time.  Each  sample  was  assayed  in 
triplicate. 
Preparation of C3bi and a Soluble,  Monomer# Probe: 
C3bi-AP 
C3bi  and a  soluble,  monomeric  conjugate  of C3bi  and AP 
were prepared as described (6).  Briefly, a sulffiydryl was first  in- 
troduced into AP with the bifunctional crosslinker, SPDP.  C3bi 
with  a  single free  sulflaydryl  was  purified  from  normal human 
plasma  using an  activated  thiol-Sepharose  column and  further 
purified with a Mono Q  column. Purified C3bi was then mixed 
with equimolar 2-pyridyl-disulfide-AP and rotated at room tem- 
perature  for 24  h.  Conjugated and free proteins were  separated 
with a Mono Q  colunm eluted with a gradient (0-1  M) of NaC1. 
The resulting 1:1 conjugate of C3bi and AP was verified by elec- 
trophoresis on a native acrylamide gel (8-25%) and by immuno- 
precipitation using mAb against C3bi as previously described (6). 
Binding of C3bi-AP to Immobilized  CR3 
Methods for measuring the binding of C3bi-AP to CR3 were 
as described (6). Briefly, plates coated with CR3 were incubated 
with C3bi-AP for 1 h at 37~  After four washes with PBS, 5 txl/ 
well of a  fluorogenic substrate  for AP was  added.  The  fluores- 
cence  signal generated  at  21~  was  detected  over  time  as  de- 
scribed above. Each sample was assayed in triplicate. 
Purification  of a Ligand for CR3 from PMN 
Two  methods  were  used  for  purifying the  ligand  of CR3 
from PMN. 
A l~nity Purification Using Immobilized CR3.  Terasaki  plates coated 
with  or without  CR3  prepared  as  described  above  were  incu- 
bated with biotinylated PMN lysate (10 btl/well) diluted in PBS 
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10 fxl/well of 10 mM EDTA was added and incubated for 10 rain 
at room temperature to elute the proteins that bound to  CR3. 
Eluates from individual wells were pooled and concentrated using 
a microconcentrator (centricon-10; Amicon, Inc., Beverly, MA). 
Samples were analyzed by gel electrophoresis. 
Ion Exchange Chromatography.  CR3-binding proteins were puff- 
fled by two sequential  chromatographic steps on Mono Q, Biotin- 
ylated PMN lysates  (from r"al09 cells) were loaded onto a Mono 
Q-FPLC column (Pharmacia LKB)  and washed with the starting 
buffer (20 mM Tris-HC1, 0.25%  OG, pH 7.4). Proteins bound to 
the column were eluted with a gradient (0-1 M) of NaCl diluted 
in 20 mM  of Tris-HC1, 0.25%  OG, pH 7.4. All fractions were 
tested for the ability to bind CR.3.  For further purification, frac- 
tions  containing  CR3-binding proteins  were  pooled,  the  OG 
content was increased twofold, and chromatography was repeated 
with a more shallow salt gradient. Eluates were collected for mea- 
suring the binding to immobilized CR.3 and for protein analysis 
using gel electrophoresis. 
Immunoprecipitation  of Proteins from PMN Lysates 
Antibodies were coupled to GammaBind G-Sepharose by in- 
cubating the beads (15 1.tl) with antibodies (35 ~g in 50 I*1 PBS) 
for 2 h at 4~  After washing with PBS, antibody-coupled Sepha- 
rose beads were incubated with biotinylated lysates of PMN (250 I-fl) 
for 1 h at 37~  After thorough washing, beads were mixed with 
SDS sample buffer and boiled for 6 rain. Polypeptides were ana- 
lyzed by SDS-PAGE (8-25%)  and Western blot using the Phast 
Gel system (Pharmacia LKB) according to the manufacturer's in- 
structions. 
Binding of PMN to Fibrinogen-coated  Surfaces 
Adhesion of PMN to fibrinogen-coated surfaces was measured 
as  described  (17),  except  that  all protease  inhibitors were  ex- 
cluded. Briefly, freshly isolated PMN  (5  ￿  106 cells/M) diluted 
in PBS,  0.1% HSA (PBS-HSA) were fluorescently labeled with 
CFSE.  Fluorescein-labeled PMN  were  added  to  fibrinogen- 
coated plates and incubated at 37~  for increasing times in the 
presence or absence of agonists.  The  fluorescence in  each well 
was measured before and after washing with a Cytofluor  TM 2300 
fluorescence plate reader. Binding is expressed as the percentage 
of cells remaining in the well after the washing step. 
Transmigration of PMN across Fibrinogen-coated  Surfaces 
Translucent cell culture inserts (pore size 3 ~M, Becton Dick- 
inson Labware, Bedford, MA) were coated with purified fibrino- 
gen  (200  ~g/n~l diluted in PBS,  150  ~l/insert) for 1 h  at room 
temperature and washed with 500 ~1 PBS.  PMN were prepared 
and fluorescently labeled with CFSE as described (17) except that 
all protease inhibitors were excluded. Fluorescently labeled PMN 
(200  I.tl at 5  ￿  1if' cells/nil) and mAb (10  Ftg/ml) in PBS-HSA 
were added to the upper compartment of each insert. Chemoat- 
tractant C5a  (0.5  btg/ml) in PBS-HSA was added to the lower 
compartment (300  btl/well). Plates were incubated for 50 min at 
37~  At the end of the incubation, individual inserts were gently 
shaken  to  dislodge PMN  from the  lower surface of the  insert. 
The number of transmigrated PMN in individual wells was deter- 
mined by measuring the fluorescence signal using a Cytofluor  TM 
2300 fluorescence plate reader. Results are expressed in arbitrary 
fluorescence units. Each sample was assayed in triplicate. 
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FA CS  ~ Analysis 
Freshly isolated PMN  (5  ￿  106  cells/ml) in PBS-HSA were 
incubated with or without C5a (0.5  b~g/ml) for increasing times 
at 37~  Cells were washed and incubated with  antibodies (10 
~g/rnl)  for 20 min on ice, washed, and further incubated with 
fluorescein-conjugated  secondary  antibody  [FITC-conjugated 
goat anti-rabbit IgGF(ab')2, 1:200]  for 45 rnin on ice. Cell-asso- 
ciated fluorescence was analyzed on a FACScan  |  flow cytometer 
(Becton Dickinson Immunocytometry System, San Jose, CA). 
Electrophoresis and Western Blot 
SDS-PAGE and Western blotting were done using either the 
Novex system (NOVEX,  San Diego, CA) or the Phast Gel sys- 
tem according to the manufacturers' instructions. Proteins were 
transfered to nitrocellulose or Immobilon membranes (Millipore, 
Corp.), and the membranes were blocked with  10% nonfat dry 
milk in PBS for 1 h at room temperature. After four washes with 
PBS, 0.1% Tween 20, biotinylated proteins were detected by in- 
cubating the membranes with streptavidin-conjugated horserad- 
ish peroxidase (1:300  dilution) diluted in PBS, 0.1%  Tween 20, 
for 30 rain at room temperature. Membranes were washed again, 
and  the  bound  streptavidin-conjugated horseradish  peroxidase 
was detected using an enhanced chemiluminescence kit. 
Amino Acid Sequencing 
After  SDS-PAGE,  proteins  were  transfered  to  Immobilon 
membranes and briefly stained with Coomassie blue. The stained 
bands  were  excised  and  subjected  to  microsequencing  at  the 
Rockefeller University protein sequencing facility. 
Results 
PMN  Contain  Ligand(s) for  the  Leukocyte  Integrin CR3. 
Purified immobilized CR.3  was incubated with AP-conju- 
gated C3bi  (C3bi-AP)  in the presence of detergent lysates 
of PMN or antibodies. As expected, the binding of C3bi to 
CR.3 was completely inhibited by mAb against the [3 chain 
(IB4) or the c~ chain (44a) of CP,.3  (Fig. 1 A), enhanced by 
the  CR.3-activating mAb KIM-127  (anti-CD18),  and  un- 
affected by a control mAb 3C10  (anti-CD14). Addition of 
PMN  lysates  also  completely blocked  binding  of ligand 
C3bi (Fig. 1 A, last column on the right), suggesting the pres- 
ence  of a  competing ligand.  To  confirm  the  presence  of 
such  a  ligand,  PMN  lysates  were  biotinylated and  incu- 
bated with immobilized CP,3,  and  bound  ligand was  de- 
tected with AP-conjugated avidin (Fig.  1 B).  Biotinylated 
soluble proteins  from  PMN  bound  significantly better  to 
immobilized  CR.3  than  to  uncoated  plastic,  and  binding 
was  completely inhibited  by  a  mAb  against  CR.3  (44a), 
whereas a  control mAb  (60b,  anti-CD14)  was ineffective. 
The  binding  was  enhanced  by  the  CP,3-activating  mAb 
KIM-127. Additional studies showed that this binding was 
also inhibited by EDTA  and  an  excess amount  of soluble 
C3bi  (not shown).  These  data thus  establish the  existence 
of a ligand for CR3 in PMN. 
Identification of an Endogenous Ia'gand  for CR3.  Because  bio- 
tinylated soluble proteins  from  PMN  bind  specifically to 
plates coated with  CP,3  (Fig.  1  B),  we  have  adapted this 
binding assay for ligand identification. Biotinylated PMN A 
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Figure 1.  Soluble proteins from PMN bind specifically  to immobilized CR3. Plastic plates coated with or without purified CR3 were incubated for 
1 h at 37~  with (A) C3bi-AP (15 nM) in the presence of the indicated mAbs (10 btg/ml) or PMN lysates (equivalent to 10  v cells/ml); or with (/3) bio- 
tinylated PMN lysates (equivalent to N5.0  ￿  106 cells/ml) in the presence of the indicated mAbs (10 btg/ml). The binding of C3bi-AP or biotinylated 
PMN lysate was quantitated by enzyme assay  as described in Materials and Methods. The results shown are representative of three independent experi- 
nlents. 
lysate  was  incubated  with  plates  coated  with  or  without 
CR3  in  the  presence  of a  blocking (IB4)  or an  activating 
mAb  (KIM-127).  After  thorough  washing,  the  proteins 
bound  to  individual wells were  eluted by adding  10  mM 
EDTA.  Eluates  were  pooled,  concentrated,  and  analyzed 
by Western blot (Fig. 2).  In the presence of KIM-127, in- 
cubation  of PMN  lysate with  CR3-coated  plates resulted 
in a specific enrichment of a  single band with a  molecular 
mass of 28  kD.  This 28-kD band was  absent or present in 
much lower amounts on plates without CR3  coating or on 
plates treated with a blocking anti-CR3 mAb (IB4). These 
data suggest that a 28-kD protein from PMN is a candidate 
ligand for CR3. 
To  obtain  sufficient material for  sequencing,  a  biotiny- 
lated PMN  lysate  was  subjected  to  chromatography,  and 
fractions  were  assayed for  their  ability to  bind  CR3  (see 
Materials and Methods). Assays for binding to CR3-coated 
plates in the presence  of a blocking mAb  (44a)  or an acti- 
vating  mAb  (KIM-127)  revealed  two  regions  of activity 
with peaks at fraction numbers 27  and 41  (Fig. 3  B). Frac- 
tion  27  contained  several  species,  including a  band  at  28 
kD.  In fraction 41,  on the  other hand,  a  single band at 28 
kD predominated (Fig. 3  C). Microsequencing of the NH 2 
terminus for this band revealed high similarity to a group of 
azurophilic granule proteins including HLE (18), protease 3 
(NP3)  (19),  azurocidin (20),  and cathepsin G  (21)  (Fig. 4). 
These proteins are characterized as neutral serine proteases 
(except azurocidin, which has no enzyme activity) and are 
normally stored at high  concentration  (1-2 pg/cell) in the 
azurophilic granules of PMN  (for review see references 22- 
24).  The  sequence  data lead to  the  hypothesis that  azuro- 
phil granule proteases may interact with CR3,  and this hy- 
pothesis was tested using purified proteins. 
Purified HLE Binds  CR3  Specifically.  Although  NP3 
showed the best apparent match to our sequence data (Fig. 
4), we focused our attention first on HLE, the best charac- 
terized  protein  in  this  family.  Purified  biotinylated  HLE 
bound  specifically to  immobilized CR3  (Fig.  5  A).  The 
binding was inhibited by blocking mAbs against CR3  (IB4, 
44a), enhanced by an activating mAb (KIM-127),  and un- 
affected  by  a  control  mAb  (3C10).  Binding  was  also 
blocked by a mAb directed against HLE (NP57).  NP57 ap- 
pears to block binding by interacting with a specific site on 
HLE,  because a  second anti-HLE mAb,  no.  204,  failed to 
block binding to  CR3  (not shown).  The  binding of HLE 
to  CR3  was  concentration  dependent  (Fig.  5  B),  and  the 
concentration  of HLE  required  for  half maximal binding 
was ,'~  I~M, suggesting that the binding was of fairly low 
affinity. Additional studies showed that the binding of riLE 
Figure 2.  Identification of a ligand for CR3 from PMN.  Plates coated 
with or without CR3 were incubated with biotinylated  PMN lysate  for 1 h 
at 37~  in the presence of  buffer, mAb IB4, or KIM-127 (10 I~g/ml). Af- 
ter thorough washing, the proteins bound to individual wells were etuted 
with  10 mM EDTA. Eluates from 216 Terasaki wells (I0 bU/well) were 
pooled, concentrated, analyzed by SDS-PAGE (4-20%) under reducing 
(with  dithiothreitol  [DTT]) or  nonreducing  conditions,  and  Western 
blotted with streptavidin-conjugated horseradish peroxidase as described 
in Materials and Methods. 
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ligand for CR3 from PMN. Bi- 
otinylated  PMN  lysates (from 
~109 cells) were injected onto a 
Mono  Q  column  and  eluted 
with a gradient of NaC1 (0-1 M) 
(not  shown).  Fractions contain- 
ing CR3-binding proteins,  de- 
termined by measuring the bind- 
ing  to  immobilized  CR3  as 
described in Materials and Meth- 
ods, were  pooled,  the detergent 
(OG)  content  was  increased 
twofold,  and  chromatography 
was  repeated  with  buffer  con- 
taining  0.5%  OG  and  with  a 
more  shallow salt gradient  ([A] 
OD2s  0  of  eluted  proteins).  (B) 
Fractions from A were tested for 
their ability to bind immobilized 
CR3 in the presence ofmAb 44a 
(10  ~tg/ml;  black bars) or KIM- 
127  (10  btg/ml; gray bars). (C-') 
Fraction  number  41  from  A, 
corresponding  to  0.87  M  of 
NaC1,  was  analyzed  by  SDS- 
PAGE (4--20%) and stained with 
Coomassie brilliant blue (Lane I) 
molecular mass markers; (lane 2), 
fraction number 41. 
to  CR3  was  also  dependent  on  divalent  cations  and  that 
purified HLE inhibited the binding of C3bi or biotinylated 
PMN  lysate to CR3  in a  concentration-dependent manner 
(data not shown).  Taken together,  these  data indicate that 
HLE can bind to CR3  in vitro. 
Additional studies suggest that HLE binds CR3  on PMN. 
Immunoprecipitation of riLE from PMN  lysates with mAb 
no. 204,  a  mAb which does not block the binding of HLE 
to  CR3,  yielded not only HLE  (not shown) but also CR3 
(Fig.  5  C).  The  amount  of CR3  precipitated  with  anti- 
HLE  was  less than the  amount precipitated  with  a  mono- 
clonal anti-CR3,  suggesting that not all of the CR3  is oc- 
cupied  by  HLE.  It  is  interesting to  note  that  only the  [3 
chain of CR3  was  detected  in the  anti-HLE immunopre- 
cipitates.  A  potential  explanation of these  findings is  pro- 
teolytic  cleavage  of the  r  chain  by  HLE  during  sample 
preparation. 
Role  of Proteolytic  Activity  in  Binding  of FILE  to  CR3. 
HLE is a potent serine protease.  The presence of a catalytic 
triad that consists of three active site residues (His-57, Asp- 
102,  and Ser-195)  enables HLE  to cleave a large variety of 
substrates (for review see reference 23). To determine if the 
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active site of HLE is involved in binding to CR3, we mea- 
sured the  binding of HLE  to  CR3  in the  presence  of the 
serine  protease  inhibitor DFP,  which  covalently modifies 
Ser-195.  As  shown in Fig.  6,  addition of DFP  completely 
blocked the binding of HLE to CR3.  In additional experi- 
ments, we tested  the effect of the naturally occurring HLE 
inhibitors,  cx-2-macroglobulin  and  oL-l-antitrypsin  (25), 
and found that both blocked  the binding of HLE  to  CR3 
(not  shown).  These  results  suggest  that  reactants  that  oc- 
cupy the active site of HLE prevent binding to CR3.  Con- 
Sample 
I  VX  X  H  E  A  Q  P  I  1  Q  P  Y  MA  F  L  Q 
L  L  1  D  G  N  S  R  G  D  M  N  V 
H 
HLE  I  V  G  G  R  R  A  R  P  H  A  WP  F  M  V  S  L  Q 
Proteiaase3  I  V  G  G  H  E  A  Q  P  H  S  R  P  Y  M  A  S  L  Q 
CathepsinG  I  1  G  G  R  E  S  R  P  H  S  R  P  Y  M  A  Y  L  Q 
Azurocidin  |  V  G  G  R  K  A  R  P  R  Q  F  P  F  L  A  S  I  Q 
Figure  4.  Comparison  of the NH2-terminal  sequences obtained  from 
fraction 41  in Fig. 3 with those for known azurophilic granule proteins 
(18-21).  Sequence analysis of fraction 41 resulted uncertainty with some 
amino acids as indicated. Figure 5.  HLE binds specifically  to CR3. Plates  coated with CR3 were incubated with (A) 25 Ixg/ml ofbiotinylated HLE in the presence of the indi- 
cated mAbs (25 la.g/ml) or (/3) increasing concentrations ofbiotinylated HLE in the presence of buffer (Ill) or mAb 44a (25 lag/nil; Q). Binding ofbio- 
tinylated HLE was quantitated as described in Materials and Methods. (t-"2) Protein G-Sepharose beads coated with the indicated mAbs were incubated 
with a biotinylated lysate of PMN for 1 h at 37~  Proteins bound to the beads were analyzed by SDS-PAGE (8-25%) and Western blotting with anti- 
CR3 as described in Materials and Methods. 
sistent  with  these  findings,  we  found  that  NP57,  a  rnAb 
which blocked the binding of HLE to CR3  (Fig. 5 A), also 
blocked the proteolytic activity of HLE (not shown). 
To  determine  if protease activity per se  is necessary for 
binding to CR3, we explored the binding activity of azuroci- 
din.  This  protein  has  high  sequence  homology  (45%)  to 
HLE but is proteolytically inactive because two  of the ac- 
tive site residues of the catalytic triad (His-57 and Ser-195) 
are  altered  (23,  10).  We  found  that  purified biotinylated 
azurocidin bound specifically (Fig. 7 A) and saturably (Fig. 
7  /3)  to  immobilized CR3.  The  avidity of azurocidin for 
CR3  (~176  nM  for  half  maximal  binding)  appeared 
slightly greater than  that for HLE  (~1  IxM for half-maxi- 
mal binding).  In keeping with its lack of proteolytic activ- 
ity, DFP showed no effect on the binding ofazurocidin to 
CR3.  Specificity of the azurocidin binding was shown  by 
inhibition with a blocking mAb against CR3  (44a) and en- 
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Figure 6.  Effect  of protease inhibitor on the binding of HLE to CR3. 
Plates coated with CR3 were incubated with increasing concentrations of 
biotinylated HLE in the presence (O) or absence (Ill) ofprotease inhibitor 
I)FP (5 raM) for t  h at 37~  After thorough washing, bound biotiny- 
lated HLE was quantitated as described in Materials  and Methods. 
hancement  with  activating mAb  KIM-127.  These  results 
thus  indicate  that  neither proteolytic activity nor  residues 
His-57  or  Ser-195  of the  catalytic triad  are  necessary  for 
binding to CR3. 
Regulation  of PMN  Adhesion  and  Ckemotaxis  by  HLE. 
Previous studies have demonstrated strong expression of HLE 
at the surface of PMN (26) as well as the release of riLE from 
PMN  and  monocytes  in  response  to  a  variety  of stimuli 
(27).  To  determine if HLE could interact with cell surface 
CR3  in a  way that affects cell adhesion, we first measured 
surface expression of HLE  and  CR3  on PMN  exposed to 
C5a (Fig. 8). These studies used a polyclonal anti-HLE that 
did  not  block  binding  of  HLE  to  purified  CR3  (not 
shown).  As expected, resting PMN  expressed a  high level 
of CR3,  and stimulation of PMN  with C5a increased sur- 
face level of CR3  (Fig. 8 A). We found that resting PMN 
also expressed a  significant level of HLE  (Fig. 8  B)  consis- 
taut  with  recent  findings  (26).  Stimulation  of PMN  with 
C5a  led to  an  extremely rapid loss of surface  HLE.  PMN 
washed immediately after the addition of C5a showed sig- 
nificant loss of HLE  (0 min;  Fig. 8  /3).  This was  followed 
by a time-dependent recovery of cell surface HLE, presum- 
ably derived from secreted granules.  The  rapid loss of cell 
surface HLE occurred in advance of enhanced CR3-medi- 
ated  adhesion,  and  the  recovery  of cell  surface  HLE  oc- 
curred  in  advance  of cell  detachment  (see  Fig.  9).  These 
data are thus consistent with the hypothesis that HLE could 
function in the regulation of CR3-mediated cell adhesion. 
To  determine  the  role  of HLE  in  PMN  adhesion,  we 
measured  the  binding  of PMN  to  fibrinogen-coated sur- 
faces (Fig. 9). Consistent with reported data (2), addition of 
C5a led first to  strong PMN  adhesion by  10  mm  and  de- 
tachment by 40 rain. As expected, an anti-CR3 mAb com- 
pletely blocked  adhesion  (not  shown),  whereas  a  control 
mAb (anti-CD14) had no effect. Addition ofa mAb against 
HLE  (NP57)  that blocks its interaction with CR3  in vitro 
had two effects on cell adhesion. When PMN  were treated 
with C5a and NP57,  the mAb completely blocked the de- 
tachment  of PMN  from  the  fibrinogen-coated  surfaces. 
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This  finding strongly implicates  HLE in release  of leuko- 
cyte  integrins  from  their  substrate.  Second,  PMN  incu- 
bated  with  NP57  in  the  absence  of stimulation  showed a 
slow,  spontaneous  binding  to  fibrinogen.  This  finding  is 
consistent  with  the  observation  that  there  is  HLE  on  the 
surface of resting PMN and suggests that HLE may play a 
role in the control of CR3 binding activity even in resting 
cells.  Because  NP57 and CR3  compete for binding HLE, 
NP57  may promote  the  dissociation  of HLE  from CR3, 
leaving the CR3 free to bind ligand. 
Movement  of PMN  out  of the  vasculature  involves  a 
firm adhesion followed by a prompt release of the adherent 
cells.  To  detenmne  if the  effect of anti-HLE  antibody on 
PMN adhesion would also influence the migration process, 
we measured the transmigration of PMN across fibrinogen- 
coated filters  (Fig.  10).  In response  to the  chemoattractant 
CSa, PMN move across the membranes and into the lower 
chamber of the chemotaxis apparatus.  As expected, migra- 
tion  of PMN  was  completely blocked by rnAb anti-CR3 
(IB4), because anti-CR3  prevents the initial attachment of 
PMN to fibrinogen-coated membranes. Addition ofa mAb 
against HLE (NP57)  decreased transmigration  of PMN  by 
40%.  No  inhibition  was  observed  when  a  control  mAb 
(60b)  was  added.  Because  NP57  blocked  detachment  of 
adherent  cells  from fibrinogen-coated surfaces  (Fig.  9),  the 
decrease  in  transmigration  may  derive  from  an  absent  or 
delayed release of the adherent PMN from the substrates. 
Discussion 
FILE Is an Endogenous Ligand  for CR3 
We have shown that PMN  contain endogenous ligands 
for  CR3  and  that  HLE  and  azurocidin  are  among these 
ligands.  Both of these  proteins  bound specifically to puri- 
fied CR3, and preliminary data suggest that NP3 may bind 
as well  (Cai,  T.-Q.,  and  S.D.  Wright,  unpublished  obser- 
vations).  HLE,  NP3,  and  azurocidin  are  structural  homo- 
logues  and  are  stored  together  in  azurophilic  granules. 
These proteins may act as a class to ligate CR3. 
We have also shown that HLE modulates leukocyte ad- 
hesion.  Blockade  of HLE with mAb NP57 prevented  de- 
tachment of PMN from a fibrinogen-coated surface (Fig. 9) 
and decreased chemotactic movement of PMN across a fi- 
brinogen-coated  surface  (Fig.  10).  Because  cell  surface 
HLE increases  before  cell detachment  (Fig.  8),  our results 
are consistent with the hypothesis that HLE may normally 
act to weaken integrin-mediated  attachment of cells  to the 
substrate  by acting as a  competitive ligand.  HLE may also 
affect  adhesion  through  proteolytic  cleavage  of substrate 
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Figure  8.  Expression  of CR3  and HLE  on 
PMN. PMN (5 X 106 cells/ml) were incubated 
with (0)  or without (')  C5a (0.5  p,g/ml) for 
the indicated amount of times at 37~  Cells were 
washed and stained with no  1  '} antibody (O), 
rabbit anti-CR3  (A)  or  anti-HLE  (B)  as  de- 
scribed  in Materials  and Methods.  Cell-associ- 
ated fluorescence  was analyzed on a FACScan  | 
flow cytometer.  Results were expressed by mean 
fluorescence  intensity. 100 - 
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Effect ofanti-HLE on the adhesion of PMN to fibrinogen- 
coated surfaces. Plates coated with fibrinogen were incubated with fiuo- 
rescently labeled PMN for increasing amounts of times at 37~  in the 
presence of buffer (m), NP57 (10 l~g/ml, O), 60b (10 b~g/ml; O), C5a 
(0.5 ~g/ml,/~), C5a plus NP57 (O), or CSa plus 60b (~). The percent- 
age of PMN adhered to the plates was quantitated as described (17). 
proteins. We wish to point out that NP57 reduced chemo- 
taxis by  "-'40%  but  did not  block it  completely.  Proteins 
other  than  HLE  may  thus  participate  in  detachment  of 
PMN from surface-bound ligands, a result consistent with a 
role for azurocidin, NP3, and perhaps other proteins in this 
function.  Recent  studies have  suggested that heparin may 
serve as a ligand for CR3  (28), and release ofheparin from 
PMN  granules may further promote detachment. 
Role for Proteolytic Activity of riLE 
Previous authors  have  suggested that  HLE  could play a 
role in transmigration of PMN by digesting proteins in the 
cell's path  (25,  29).  L658,758,  a  specific, low-molecular- 
weight, irreversible, active site inhibitor of HLE, was shown 
to block migration of PMN  into tissues in response to PAF 
(30)  and reperfusion (29).  This inhibitor did not affect cell 
rolling (30), suggesting that it did not act on selectins, and 
it did not block binding of PMN  to substrates in vitro (29, 
30), suggesting that it did not block the binding function of 
integrins. Woodman et al. (30) concluded that "elastase se- 
lectively enhances  or  regulates  CD18-dependent  chemo- 
taxis." Results reported here using the anti-HLE mAb NP57 
are completely consistent with the  earlier findings: block- 
ade of HLE  with  this mAb impaired chemotaxis (Fig.  10) 
but did not block integrin-dependent cell adhesion (Fig. 9). 
Our findings strengthen the conclusions of prior work, and 
the  in  vivo  studies  with  L-658,758  suggest  an  important 
role for HLE in modulating PMN  emigration. 
Our finding that HLE binds directly to CR3,  the major 
adhesion protein of PMN, suggests a mechanism by which 
this protein  affects PMN  emmigration.  HLE  may act not 
just to digest extracellular material but also to release inte- 
grins from the substrate and permit forward motion, a con- 
clusion supported by the observation that NP57 blocks re- 
lease of PMN  from a fibrinogen-coated surface (Fig. 9).  It 
is important to point out that both NP57 and active site in- 
hibitors simultaneously block two functions of HLE: bind- 
ing to CR3 and proteolytic activity. The individual contri- 
bution of these two activities thus cannot be separated. 
A  key question raised by our studies is whether HLE re- 
tains its proteolytic activity when bound to CR3.  On one 
hand, Altieri and colleagues (31, 32) showed that the serine 
protease, Factor X, is a ligand for CR3 and that binding to 
CR3  modulates but does not block the proteolytic activity 
of Factor X.  Moreover,  HLE present at the PMN  surface 
has  been  shown  to  be  proteolytically active  against small 
molecule  substrates  (26).  On  the  other  hand,  there  are 
many  more  binding  sites  for  HLE  on  the  PMN  surface 
than molecules of CR3 (26, 33), and it is not clear whether 
the  active cell surface  HLE  is bound  to  CR3  or to  some 
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Figure 10.  Effect  of anti-HLE on the transmigration of 
PMN across fibrinogen-coated surfaces. Fluorescently la- 
beled PMN (5 X 106 cells/ml) and the indicated mAbs (10 
lag/rid) were added to the upper compartment of cell cul- 
ture inserts coated with fibrinogen. Chemoattractant C5a 
(0.5 p,g/ml) was added to individual wells of the compan- 
ion plate￿9 After a 50-rnin incubation at 37~  the inserts 
were removed, and the number of PMN migrated through 
the inserts was quantitated as described. Results were ex- 
pressed by arbitrary fluorescence units￿9 
Elastase: A Ligand for the Leukocyte Integrin CR3 other structure.  Additionally,  occupation  of the  active site 
of riLE with the small molecule, DFP,  completely blocked 
binding to CR3  (Fig. 6). This observation suggests that the 
active site  of HLE  is directly involved in interaction  with 
CR3  and  would  thus  be  unavailable  for interaction  with 
substrates.  Studies  are  underway  to  address  this  issue.  It is 
noteworthy  that recent  work from several laboratories  has 
described a new class of proteins that express both an inte- 
grin-binding domain and a protease domain (for review see 
reference  34).  A  clear  function  for this  group  of proteins 
has not been described, but the finding raises the possibility 
that association with a protease may be a general feature of 
integrins. 
A  New Model for Regulation q[PMN Adhesion 
Cell Attachment to Substrate.  Stimulation  of PMN  adhe- 
sion clearly involves alterations in the binding properties of 
CR3  itself.  Stimulation  of ceils  with  chemoattractants  or 
PMA  causes  CR3  to  exhibit  neoepitopes  recognized  by 
certain  mAbs  (35,  36),  and  the  anti-CR3  mAb  KIM-127 
causes both enhanced  binding of cells to substrate  (14)  and 
enhanced  binding  of purified  CR3  to  purified  ligand  (6). 
Although the change in CR3 caused by cell stimulation has 
been  frequently  described  as  an  enhancement  in  affinity, 
our recent work suggests that binding kinetics,  not affinity, 
may be  altered  (6).  Activation  of purified  CR3  by KIM- 
127  was  found  to  be  isoenergetic,  a  result  incompatible 
with a significant change in binding affinity. Moreover, the 
activation  energy for binding  of C3bi  to  active  CR3  was 
found to be very high (15 kcal/mol), suggesting that the ki- 
netic barrier to ligand binding is very significant and that a 
relatively slight increase in this barrier could effectively halt 
ligand  binding  in  the  time  range  (minutes)  available  to  a 
neutrophil  on  a  substrate.  The  model  that  has  emerged 
from these studies is that cell stimulation  enhances  the rate 
of ligand binding by CR3  and  thereby enables binding  of 
cells to substrate-bound ligand.  Our finding of endogenous 
ligands for CR3  does not significantly affect this portion of 
the  model:  whether  inactive  receptors  are  occupied  by 
HLE or not,  they are equally incapable of interacting with 
substrate-bound  ligand  because  of slow  binding  kinetics. 
Upon activation of cells, the accelerated binding kinetics of 
CR3 should give HLE the opportunity to disassociate and/ 
or to equilibrate with other ligands.  It should be noted that 
the  affinity  of CR3  for  C3bi  (15  nM)  is  at  least  50-fold 
greater  than  that  for HLE.  Binding  of CR3  to  substrate- 
bound C3bi may thus be favored. 
Cell Detachment.  In  contrast  with  their  small  effect on 
initiating  cell attachment,  endogenous  ligands  are likely to 
play a large role in reversing cell adhesion. Binding of CR3 
to the representative ligand,  C3bi, occurs with a high affin- 
ivy (15 nM). Alterations in binding kinetics can have no ef- 
fect once this energetically favorable reaction is completed, 
and alterations in binding kinetics cannot cause cell detach- 
ment. As we have pointed out previously (6), an additional 
step,  distinct  from the  energetically  neutral  effect on inte- 
grin activation, is required  to reverse adhesion.  We suggest 
that endogenous  ligands such as  HLE may accomplish  this 
step. Azurophilic granules contain very high concentrations 
of HLE, NP3, and azurocidin.  Fusion of granules near sites 
of adhesion may "elute" substrate-bound ligand from CR3 
and cause detachment.  Consistent with this model, our data 
show that blockade of riLE with a mAb blocks detachment 
of PMN  from a fibrinogen-coated  surface  (Fig.  9). As dis- 
cussed above, the proteolytic activity of these proteins may 
have an additional  effect on adhesion. 
In summary, these studies suggest a novel mechanism for 
controlling  CR3-mediated  adhesion.  Because  other  inte- 
grins,  such  as  LFA-1  of lymphocytes  and  gplIb/IIIa  of 
platelets, show behavior remarkably similar to that of CR3 
(37,  38),  it will be of interest  to  determine  if endogenous 
ligands  could play a  role in  regulation  of these  molecules. 
Because HLE and other granule constituents  may accumu- 
late to high levels in diseases such as cystic fibrosis (39, 40), 
our observations may also provide a link to the pathogene- 
sis of some inflammatory diseases. 
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